DOASENSE
DOASENSE GmbH develops the first urine-based point-of-care test for Direct Oral Anticoagulants, serving emergency departments, stroke units, and surgical settings across 15+ countries via exclusive distributors. Founded 2016 in Heidelberg; pending acquisition by CoaguSense/i-SENS.
- Company typePrivate
- Founded2016
- HeadquartersHeidelberg, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What DOASENSE does
DOASENSE GmbH is a Heidelberg-based medical technology company that developed the first urine-based point-of-care test for Direct Oral Anticoagulants (DOACs). Its flagship product, the DOAC Dipstick, is a colorimetric test strip that qualitatively detects the four major DOACs—Dabigatran, Apixaban, Edoxaban, and Rivaroxaban—within 10 minutes from a urine sample, addressing an unmet clinical need for rapid anticoagulant status assessment in emergency stroke, trauma, and pre-operative scenarios. The product line is complemented by the DOASENSE Reader, a compact semi-automatic photometric device for objective documentation of test results, and DOASENSE Control Urines, quality-control reference substances. The underlying technology is patent-protected and was developed by founders with 35+ years of coagulation research at Heidelberg University.
The company sells exclusively through a network of independent medical-device distributors covering 15+ countries, with named partners including Hitado/Sysmex (Germany, Austria, Switzerland), Eurobio Scientific (France), A. DE MORI (Italy), Haemoview Diagnostics (Australia/New Zealand), KBM Pharm (South Korea), SUNMEDCARE (Brazil), AB Scientific (UK), BIOMETA (Portugal/Spain), Mediq Eesti (Estonia), Medista (Czech Republic/Slovakia), and Philcare (Philippines). Customers are institutional healthcare providers—hospitals, emergency departments, stroke units, surgical and orthopaedic departments, and clinical laboratories—with pricing handled via quote-based distributor agreements. Regulatory positioning is a core asset: the DOAC Dipstick and DOASENSE Reader are IVDR-CE certified under EU 2017/746, and the product is included in the British Society of Haematology guidelines, ESAIC guidelines, and the German G-BA guideline on hip fracture care.
Founded in 2016 in Heidelberg by Prof. Dr. med. Job Harenberg and Prof. Dr. Roland Krämer, DOASENSE has remained a privately held micro-cap company with 1-10 employees and no disclosed institutional funding rounds. In March 2026, CoaguSense, Inc.—a Fremont, California-based subsidiary of i-SENS, Inc.—announced a definitive asset purchase agreement to acquire DOASENSE's DOAC testing business, with closing expected within 12 months, signalling an exit through strategic acquisition into a larger coagulation-monitoring platform.
DOASENSE firmographics
Firmographics- Name
- DOASENSE
- Legal name
- DOASENSE GmbH
- Website
- https://doasense.de
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DOASENSE GmbH develops the first urine-based point-of-care test for Direct Oral Anticoagulants, serving emergency departments, stroke units, and surgical settings across 15+ countries via exclusive distributors. Founded 2016 in Heidelberg; pending acquisition by CoaguSense/i-SENS.
- Ownership category
- akta.pro rank
DOASENSE industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine) (HLAHAOAE)
- akta.pro secondary industries
- Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status) (HLAHAKAJ), Point-of-Care & Decentralized Trial Testing Services (HLAGAEAK), Clinical Chemistry, Hematology & Coagulation Testing (Trial Support) (HLAGAEAE)
Keywords
Where DOASENSE is headquartered
LocationHeadquarters
- HQ city
- Heidelberg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
DOASENSE business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- DOAC Dipstick Test Strips: Sale of single-use diagnostic test strips for point-of-care DOAC detection. One pack includes 12 tests. Products are for professional healthcare use only.
- DOASENSE Reader Device: Sale of semi-automatic reader device for objective documentation of test results. The device provides photometric reading of dipstick colors.
- DOASENSE Control Urines: Sale of quality control reference substances for quality assurance testing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing through authorized distribution partners |
Go-to-market motion1 record
Distribution channels9 records
Marketing channels6 records
DOASENSE product offering
Product offeringCore offering
DOASENSE develops and sells a urine-based point-of-care testing suite for Direct Oral Anticoagulants (DOACs). The flagship product is the DOAC Dipstick, a single-use colorimetric test strip that qualitatively detects the presence of Dabigatran, Apixaban, Edoxaban, and Rivaroxaban in urine within 10 minutes. The suite also includes the DOASENSE Reader, a compact semi-automatic photometric device for objective documentation of results, and DOASENSE Control Urines, reference substances for quality assurance.
Product overview
DOASENSE offers a unified product suite for point-of-care testing of Direct Oral Anticoagulants (DOACs). The core product is the DOAC Dipstick—a urine-based test strip that detects the presence or absence of DOACs (Dabigatran, Apixaban, Edoxaban, Rivaroxaban) within 10 minutes. This is supported by the DOASENSE Reader, a compact semi-automatic device that provides objective photometric documentation of test results. DOASENSE Control Urines serve as quality control reference substances. All products are IVDR/CE marked in vitro diagnostic medical devices intended for professional use in healthcare settings.
Differentiator
Problem solved
Functional benefit
Brands
- DOAC Dipstick: First point-of-care test that uses urine samples to detect direct oral anticoagulants (Dabigatran, Apixaban, Edoxaban, and Rivaroxaban) and provide qualitative results within 10 minutes
- DOASENSE Reader
- DOASENSE Control Urines
Products and services
- DOAC Dipstick Single-use colorimetric point-of-care test strip that uses urine samples to detect the presence of direct oral anticoagulants — Dabigatran (thrombin inhibitor) and Apixaban, Edoxaban, and Rivaroxaban (Factor Xa inhibitors) — and provides qualitative results within 10 minutes. Includes dedicated pads for thrombin inhibitors, Factor Xa inhibitors, urine color correction, and creatinine detection. IVDR-CE marked and intended for professional healthcare use only in clinical settings such as emergency departments, stroke units, and surgical departments.
- DOASENSE Reader Compact, semi-automatic reader device that provides photometric, objective documentation of DOAC Dipstick test results as an alternative to visual interpretation. Compliant with IVDR (EU) 2017/746 and intended for healthcare professional use alongside the DOAC Dipstick.
- DOASENSE Control Urines Specially designed reference substances used to support quality assurance and verification of DOAC Dipstick test performance. IVDD CE marked and intended for healthcare professional use alongside the DOAC Dipstick.
Quantifiable outcome
- Results available within 10 minutes vs. traditional blood tests
- +2 more outcomes
Companies that use DOASENSE
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
DOASENSE technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
DOASENSE partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered flagship, core and minor.
- CoaguSense, Inc. (i-SENS subsidiary)flagshipCoaguSense, Inc., a Fremont, California-based subsidiary of i-SENS, Inc., has entered into a definitive asset purchase agreement to acquire the DOASENSE DOAC testing business. The acquisition includes the flagship DOAC Dipstick technology, DOASENSE Reader, and Control Solutions. The transaction is expected to close within 12 months subject to customary conditions. This would expand CoaguSense's portfolio from traditional Vitamin K Antagonist monitoring into the rapidly growing DOAC market.
- Haemoview DiagnosticscoreExclusive distributor for Australia and New Zealand. Haemoview also organized webinars on DOAC Testing in Critical Care and hosts the DOASENSE webinar content on their platform.
- Eurobio ScientificcoreAppointed as exclusive distributor of DOASENSE solutions in France. Partnership announced May 2023.
- A. DE MORI S.p.A.coreAppointed as exclusive distributors of DOASENSE solutions in Italy. Partnership announced September 2020. DOASENSE is recommended POCT for Andexanet alpha (ONDEXXYA) prescription in Tuscany, Italy.
- KBM Pharm Co., LtdcoreAppointed as exclusive distributor addressing markets in South Korea. Partnership announced May 2020.
- Hitado GmbH / SysmexcoreHitado serves as distributor for Germany. Sysmex Austria and Sysmex Suisse serve Austria and Switzerland respectively. DOASENSE exhibited at SYSMEX booth at multiple congresses.
- SUNMEDCAREcoreAppointed as exclusive distributor for Brazil. Partnership announced November 2020. ANVISA approval received May 2021.
- Mediq Eesti OÜcoreAppointed as exclusive distributor for Estonia. Partnership announced January 2022. DOASENSE is embedded in anaesthesia guidelines in Estonia.
- BIOMETA Tecnologia y SistemascoreAppointed as exclusive distributor for Portugal and Spain. Partnership announced January 2021, expanding availability to these markets.
- Philcare Pharma Inc.coreAppointed as exclusive distributor for the Philippines. Partnership announced September 2023.
- AB Scientific UKcoreAppointed as exclusive distributor for the United Kingdom. MHRA Registration achieved October 2025.
- MEDISTA spol.s r.o.coreAppointed as exclusive distributor of DOASENSE product suite for the Czech Republic and Slovakia. Partnership announced April 2020.
- Start-up BWminorDOASENSE gratefully acknowledges support from the Start-up BW funding program for startups in Baden-Württemberg.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
DOASENSE competitors and assessment
Company assessmentBroad incumbents
- Diagnostica Stago: Diagnostica Stago is a global leader in haemostasis and coagulation diagnostics with the STA Compact Max, STA R Max and DOAC-specific testing reagents on its analyzers, making it a broad incumbent competing for the same clinical workflow of anticoagulant monitoring.
- bioMérieux: bioMérieux is a major IVD player with a haemostasis/coagulation line; board member Dr. Volker Oeding was previously Managing Director of bioMérieux Germany for 25 years, illustrating the strategic connection and overlap in specialty IVD/coagulation.
- Haemonetics: Haemonetics is a blood and coagulation management company (TEG, Cell Saver) whose advisor Remi Corlin previously built international market presence; it competes in the broader peri-procedural coagulation assessment space DOASENSE addresses.
- Helena Laboratories: Helena Laboratories manufactures specialty coagulation and haemostasis reagents and POC systems (including cascade and factor assays) used in clinical laboratories and is a comparable specialty coagulation diagnostics peer.
- Siemens Healthineers: Siemens Healthineers offers the BCS XP and Atellica COAG360 systems for coagulation/DOAC testing in central labs and operates a broad IVD/POCT portfolio; Sysmex Austria/Swiss (already a DOASENSE distributor) further connects the firms in the haemostasis space.
- Roche Diagnostics: Roche Diagnostics operates the cobas t 511/t711 coagulation analyzers with DOAC testing capability, plus the cobas Liat POCT system; its broad IVD footprint and hospital channel make it a key broad peer in both coagulation diagnostics and point-of-care testing.
- Sysmex Corporation: Sysmex is a global leader in haematology and haemostasis (CS- and CA-series coagulation analyzers) and already serves as DOASENSE's exclusive distributor in Austria and Switzerland; it competes in adjacent coagulation testing and shares distribution overlap with DOASENSE.
- Abbott Point of Care: Abbott Point of Care operates the i-STAT system, a leading handheld POCT platform used in emergency departments and hospitals worldwide; its clinical channel and rapid-test menu directly overlap with the use cases DOASENSE targets.
Direct peers
- CoaguSense: CoaguSense, Inc. (Fremont, CA) manufactures point-of-care PT/INR coagulation monitoring devices for Vitamin K Antagonist therapy and has signed a definitive agreement to acquire DOASENSE's DOAC testing business, making it the closest direct peer in specialty coagulation POCT.
Others
- Sekisui Diagnostics: Sekisui Diagnostics supplies coagulation reagents and specialty chemistry solutions to clinical labs globally; it is thematically adjacent as a reagent/instrument provider in the haemostasis testing ecosystem in which DOASENSE participates.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
DOASENSE social profiles
Digital presenceDOASENSE compliance and trust
Trust signalCompliance6 records
DOASENSE financial estimates
Financial estimateRevenue estimate
Valuation estimate
DOASENSE leadership team
Management profileNumber of profiles
Profiles6 records
DOASENSE funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DOASENSE M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DOASENSE
What does DOASENSE do?
DOASENSE develops and sells a urine-based point-of-care testing suite for Direct Oral Anticoagulants (DOACs). The flagship product is the DOAC Dipstick, a single-use colorimetric test strip that qualitatively detects the presence of Dabigatran, Apixaban, Edoxaban, and Rivaroxaban in urine within 10 minutes. The suite also includes the DOASENSE Reader, a compact semi-automatic photometric device for objective documentation of results, and DOASENSE Control Urines, reference substances for quality assurance.
Is DOASENSE a public or private company?
DOASENSE is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DOASENSE founded?
DOASENSE was founded in 2016. It employs 1 to 10 people.
Where is DOASENSE based?
DOASENSE is headquartered in Heidelberg, Germany, in the Europe region.
How does DOASENSE make money?
Three revenue lines are on record. DOAC Dipstick Test Strips are the primary driver. The others are DOASENSE Reader Device and DOASENSE Control Urines.
Who are DOASENSE's main competitors?
Broad incumbents on record are Diagnostica Stago, bioMérieux, Haemonetics, Helena Laboratories, Siemens Healthineers, Roche Diagnostics, Sysmex Corporation and Abbott Point of Care. CoaguSense is listed as a direct peer. Sekisui Diagnostics is listed as an others.
Does DOASENSE have an API?
No public API is recorded for DOASENSE.
What industry is DOASENSE in?
DOASENSE's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAOAE, Urinalysis & Kidney Function POCT (Dipstick, Microalbumin, Creatinine), with a secondary code of HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status). Its NAICS code is 325413 and its SIC code is 2835.